How effective is Bangladesh Everest Pharmaceuticals' Sotolaxib?

Sotoraxib (AMG510)is an irreversible and selective inhibitor of mutationKRAS p.G12C (KRAS G12C). KRAS G12C is one of the most common driver mutations in non-small cell lung cancer. Previously, there were no targeted drugs targeting the KRAS gene on the market globally until May 2021. The launch of sotorasiib filled this gap.

Clinical data of sotoraxib shows that the effect is still very optimistic. The half-life of sotoraxib5.5 hours, disease control rate (DCR) 80.6%, objective response rate (ORR)37.1%, duration of response (DOR) 6.8 months, median no Progression survival (mPFS) 13.6 months, median overall survival (mOS) 12.5 months, the incidence rate of adverse reactions69.8%, and the incidence rate of adverse reactions grade 3 or above 19.8%. The above is for reference only.

During the first 3 months of treatment, monitor liver function tests every 3 weeks (i.e. AST, ALT, total bilirubin< span>), then monitor monthly or as clinically indicated, More frequent monitoring may be required in patients who develop hepatotoxicity, Monitor for new or worsening pulmonary symptoms (e.g., dyspnea, cough, fever) indicative of interstitial lung disease or pneumonia. Not clear yetSotorasibuor whether its metabolites are distributed into breast milk, and it is not known whether the drug has any effects on lactation or on the breastfed infant. Because of the potential for adverse reactions to sotoraxib in breastfed infants, it is recommended that women not breastfeed during treatment with the drug and for 7 days after stopping the drug. The retail price of Bangladesh Everest Pharmaceuticals120mg56 tablets is priced from 4000 yuan to 5000 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0